FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to medicine and describes a solid pharmaceutical composition applicable for oral administration and containing: S1P receptor modulator which represents 2-amino-2-[2-(4-octylphenylethyl)]propane-1,3-diol in the free form or in the form of a pharmaceutically acceptable salt or a phosphate thereof and monocrystalline cellulose in the absence of a sugar alcohol.
EFFECT: invention provides higher storage stability of the composition.
9 cl, 40 ex, 11 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ORGANIC COMPOUNDS | 2004 |
|
RU2358716C2 |
| METHOD FOR PREPARING PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2475236C2 |
| ORAL PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2475237C2 |
| CRYSTALLINE FORMS OF FINGOLIMOD HYDROCHLORIDE | 2009 |
|
RU2549899C2 |
| PHARMACEUTICAL COMPOSITION OF SIP RECEPTOR AGONIST FOR TREATING DEMYELINIATING DISEASES | 2012 |
|
RU2506949C1 |
| METHOD OF PRODUCING CAPSULES OF FINGOLIMOD HYDROCHLORIDE | 2015 |
|
RU2577230C1 |
| COMPOSITIONS CONTAINING MODULATORS OF SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR | 2008 |
|
RU2779056C2 |
| SOLID ORAL PHARMACEUTICAL COMPOSITION OF S1P AGONIST OR ITS PHARMACEUTICALLY ACCEPTABLE SALT, METHOD FOR ITS PRODUCTION AND METHODS FOR TREATMENT AND REDUCTION OF FREQUENCY OF CLINICAL EXACERBATIONS OF MULTIPLE SCLEROSIS | 2015 |
|
RU2639424C2 |
| METHOD OF TREATING CARDIOVASCULAR DISEASES | 2012 |
|
RU2570752C2 |
| PARKINSON'S DISEASE THERAPY WITH APPLICATION OF COMBINATION WITH FIXED DOSES | 2013 |
|
RU2642962C9 |
